
We are advancing cancer care by developing next-generation therapies to address treatment resistance.
At Theseus, we believe truly transformative, targeted cancer therapeutics must simultaneously inhibit all cancer-causing and resistance mutations. We are focused on outsmarting cancer resistance by developing pan-variant therapies that inhibit cancer cell function and improve potential treatment outcomes.
Our drug development approach has three pillars:
Validated Molecular Targets
1
Validated Molecular Targets
Pursuing well-understood targets where mutations commonly emerge allows us to minimize the biological risk associated with drug development.
Unique Discovery Platform
2
Unique Discovery Platform
We use an iterative process that combines a distributed chemical structure to optimize “pan-ness” against known mutations with our novel Predictive Resistance Assay (PRA) that can accurately predict clinical outcomes of TKIs against anticipated variants.
Biomarker-Guided Design
3
Biomarker-Guided Design
We employ biomarkers early on in clinical development, allowing us to assess activity efficiently against individual mutant variants and accelerate programs accordingly to reach patients faster.
Cancer-causing and resistance mutations limit the efficacy of existing targeted cancer therapies by rendering tumor cells unresponsive to drugs. Our next-generation, pan-variant TKIs may successfully address the challenge of resistance.



We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in tyrosine kinase targets.
VIEW OUR PIPELINE